Abstract 592P
Background
Debate surrounds the surgical management of Goblet cell adenocarcinoma (GCA). However, right hemicolectomy (RHC) remains the standard surgical choice for GCA.
Methods
1154 and 867 patients with GCA were extracted from U.S. Surveillance, Epidemiology, and End Results (SEER) and National Cancer Registration and Analysis Service (NCRAS) databases respectively after excluding patients with missing data. Two clusters for each cohort were created using an unsupervised machine learning K-means model (cluster 0, cluster 1). Clustering was evaluated using silhouette (S), Davies Boulden (DB) and Caliniski Harabasz (CH) scores. Clusters were visualised using principal component analysis (PCA) and T-distributed stochastic neighbour embedding (T-SNE). SHapley Additive exPlanations (SHAP) identified clinical features that were the most useful in clustering. Kaplan Meier (KM) statistics and graphs were generated. Decision trees were developed to cluster individual patients in each of the two clusters.
Results
PCA and T-SNE visualisations showed distinct clusters with some overlap in both cohorts. SHAP revealed tumour size and stage as important variables for clustering in SEER, while age and stage were key variables in NCRAS. Clusters description and survival are shown in the table. The two clusters were statistically different in survival based on Cox regression, Log-rank test and KM statistics in both cohorts. Appendectomy and RHC showed similar survival rates across both cohorts and within each cluster of both cohorts. Table: 592P
Characteristics of clusters and 5-year survival rates
Characteristic | Clustrer 0Favourable survival | Cluster 1Unfavourable survival |
Median age, years (SEER) | 58 | 59 |
Male sex, % (SEER) | 48 | 54 |
Localised stage, % (SEER) | 64 | 33 |
Distant stage, % (SEER) | 3 | 19 |
Tumour size, median mm (SEER) | 14 | 50 |
5-year survival, % (95% CI) (SEER) | 85(82-88) | 72(59-72) |
Median age, years (NCRAS) | 48 | 68 |
Male sex, % (NCRAS) | 56 | 43 |
Localised stage, % (NCRAS) | 90 | 81 |
Distant stage, % (NCRAS) | 4 | 9 |
5-year survival, % (95% CI) (NCRAS) | 87(83-91) | 61(57-66) |
Conclusions
After categorising cases into two clusters using unsupervised machine learning, RHC and appendectomy demonstrated comparable survival rates among patients with GCA. Machine learning could facilitate clinicians in exploring the impact of various treatment approaches on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hampshire Hospitals NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16